Treatment of breast cancer is based on the molecular subtype, a classification that in the first instance takes into account the immunohistochemically assayed expression of hormone receptors estrogen receptor (ER) and progesterone receptor (PR), and gene amplification or overexpression of human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to breast cancer.